MS Drug Kesimpta Stops Disease in 91% of Patients

For the first time, real-world data confirms that people with multiple sclerosis can stop their disease from progressing when treated early with the right therapy.

Italian researchers tracked 89 adults with relapsing MS who received Kesimpta injections over three years. An impressive 91% showed no evidence of disease activity, meaning no relapses, no new brain lesions, and no worsening disability.

The self-administered therapy works by targeting immune cells that attack the protective coating around nerves. Patients can inject it at home, giving them control over their treatment schedule.

The study, published in Therapeutic Advances in Neurological Disorders, found the biggest winners were younger patients and those who started treatment before significant disability developed. Patients who maintained disease stability averaged 39 years old, compared to 48 years old for those whose disease progressed.

Cognitive function stayed stable in 69% of patients tested, meeting even stricter success criteria. Both newly diagnosed patients and those switching from other treatments responded equally well.

The treatment proved remarkably safe in everyday use. Most side effects were mild, temporary fevers after the first couple injections. Only two patients stopped treatment due to side effects, and only two ended treatment because their disease progressed anyway.

The Ripple Effect

These results challenge how many countries still treat MS. The traditional approach starts with safer, less aggressive therapies and only escalates to high-effectiveness drugs after those fail. But this study adds to mounting evidence that starting strong makes more sense.

By the time patients "earn" access to powerful therapies through years of failed treatments, irreversible nerve damage may already limit what's possible. Starting Kesimpta earlier preserved neurological function that can't be recovered once lost.

The researchers concluded these findings "support early anti-CD20 therapy as an effective strategy to preserve neurological function and limit long-term progression." For the estimated 2.8 million people living with MS worldwide, that could mean preventing disability rather than managing it.

The convenience factor matters too. Unlike infusion therapies requiring hospital visits, Kesimpta gives patients independence. They control when and where they take their medication, whether at home or traveling.

More real-world studies like this one help doctors and patients make informed choices based on how treatments perform in everyday life, not just controlled clinical trials. The results confirm what clinical trials suggested: stopping MS early, before it steals function, gives people the best chance at a full life.